Adial Pharmaceuticals announced on July 9, 2025, the filing of an update to its provisional patent application for AD04, which was initially filed in July 2024. AD04 is the company’s lead investigational genetically targeted therapy for Alcohol Use Disorder (AUD).
Once granted, this patent is expected to protect Adial’s core assets out to at least 2045. This application is the result of an extensive examination of data and information, following the hiring of new patent counsel to bolster the company’s intellectual property portfolio.
This significant extension of intellectual property protection is crucial as Adial continues to advance AD04 towards its End of Phase 2 (EOP2) meeting with the FDA. Long-term patent exclusivity enhances the commercial potential and value of AD04.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.